News and Media

NEWS AND MEDIA

Latest News

FDA clears targeted alkali thermolysis product for hyperhidrosis treatment

April 14, 2023
Read More

FDA Clears New Underarm Sweat Control Patch

April 13, 2023
Read More

The FDA Just Approved a New Patch Treatment for Excessive Sweating

April 13, 2023
Read More
View AllView Less
loudspeake

PRESS RELEASES

Candesant Biomedical Receives FDA Clearance of Brella™¹, the First and Only 3-Minute SweatControl Patch™, to Significantly Reduce Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

April 13, 2023

Pivotal Clinical SAHARA Study Shows Candesant Biomedical’s Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

March 18, 2023

Candesant Biomedical Announces Late-Breaking Oral Presentation of Pivotal Clinical Trial Data for its Investigational Patch to Reduce Excessive Underarm Sweating (Primary Axillary Hyperhidrosis) at the American Academy of Dermatology 2023 Annual Meeting

March 9, 2023

Candesant® Biomedical Announces Publication of Pilot Study Data on a Novel, Non-invasive Medical Device for the Reduction of Axillary Hyperhidrosis

November 29, 2022

View AllView Less

CLINICAL PUBLICATIONS

Optimization of the Application Procedure for the Brella SweatControl Patch

October 25, 2024

Primary Axillary Hyperhidrosis or Excessive Axillary Sweating in Aesthetics Patients: Prevalent, Mostly Undiagnosed, Embarrassing, Impairs Quality of Life, Demonstrates Need for New Treatment

June 9, 2023

 Quality of Life Improvement Shown During Sahara Clinical Study on the TAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

June 7, 2023

Outcomes from the SAHARA Clinical Study on the TAT Patch for
Excessive Axillary Sweating or Primary Axillary Hyperhidrosis

May 4, 2023

View AllClose

MEDIA KIT

LOGOS

Download

FACT SHEETS

Download

MEDIA CONTACT

For all media inquires,
please contact Suzanne Haber at

Scroll to Top